Di Minno G, Mannucci PM, Tufano A, Palaret i G, Moia M, Baccaglini U, et al. The fi rst ambulatory screening on thromboembolism: a mult icent re, cross-sect ional, observat ional study on risk factors for venous thromboembol ism. J Thromb Haemost . 2005;3:1459-66.
Decousus H, Leizorovicz A. Superfi cial thrombophlebit is of the legs: st ill a lot to learn. J Thromb Haemost . 2005;3:1149-51.
Heit JA, Silverstein MD, Mohr DN, Pet terson TM, Lohse CM, O’Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost . 2001;86:452-63.
Schönauer V, Kyrle PA, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Superfi cial thrombophlebit is and risk for recurrent venous thromboembolism. J Vasc Surg. 2003;37:834-8.
Barrellier MT. Superfi cial venous thromboses of the legs. Phlebologie. 1993;46:633-9.
De Moerloose P, Wutschert R, Heinzmann M, Perneger T, Reber G, Bounameaux H. Superfi cial vein thrombosis of lower limbs: infl uence of factor V Leiden, factor II G20210A and overweight .Thromb Haemost . 1998;80:239-41.
Bounameaux H, Reber-Wasem MA. Superfi cial thrombophlebit is and deep vein thrombosis. A cont roversial associat ion. Arch Intern Med. 1997;157:1822-4.
Binder B, Lackner HK, Salmhofer W, Kroemer S, Custovic J, Hofmann- Wellenhof R. Associat ion between superfi cial vein thrombosis and deep vein thrombosis of the lower ext remit ies. Arch Dermatol. 2009;145:753-7.
Decousus H, Epinat M, Guillot K, Quenet S, Boissier C, Tardy B. Superfi cial vein thrombosis: risk factors, diagnosis, and t reat - ment . Curr Opin Pulm Med. 2003;9:393-7.
Verlato F, Zucchet ta P, Prandoni P, Camporese G, Marzola MC, Salmist raro G, et al. An unexpectedly high rate of pulmonary embolism in pat ients with superfi cial thrombophlebit is of the thigh. J Vasc Surg. 1999;30:1113-5.
Blumenberg RM, Barton E, Gelfand ML, Skudder P, Brennan J. Occult deep venous thrombosis complicat ing superfi cial thrombophlebit is. J Vasc Surg. 1998;27:338-43.
Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M, et al; POST (Prospect ive Observat ional Superfi cial Thrombophlebit is) Study Group. Superfi cial venous thrombosis and venous thromboembolism: a large, prospect ive epidemiologic study. Ann Intern Med. 2010;152:218-24.
Gillet JL, Perrin M, Cayman R. Superfi cial venous thrombosis of the lower limbs: prospect ive analysis in 100 pat ient s. J Mal Vasc. 2001;26:16-22.
Milio G, Siragusa S, Minà C, Amato C, Corrado E, Grimaudo S, et al. Superfi cial venous thrombosis: prevalence of common genet ic risk factors and their role on spreading to deep veins.Thromb Res. 2008;123:194-9.
Milio G, Siragusa S, Malato A, Grimaudo S, Pinto A. Superfi cial venous thrombosis: role of inherited defi ciency of natural ant icoagulants in extension to deep veins. Int Angiol. 2009;28:298-302.
Gillet JL, Allaert FA, Perrin M. Superfi cial thrombophlebit is in non varicose veins of the lower limbs. A prospect ive analysis in 42 pat ients. J Mal Vasc. 2004;29:263-72.
Mouton WG, Kienle Y, Muggli B, Naef M, Wagner HE. Tumors associated with superfi cial thrombophlebit is. Vasa. 2009;38: 167-70.
León L, Giannoukas AD, Dodd D, Chan P, Labropoulos N. Clinical signifi cance of superfi cial vein thrombosis. Eur J Vasc Endovasc Surg. 2005;29:10-7.
Gorty S, Pat ton-Adkins J, DaLanno M, Starr J, Dean S, Sat iani B. Superfi cial venous thrombosis of the lower ext remit ies: analysis of risk factors, and recurrence and role of ant icoagulat ion. Vasc Med. 2004;9:1-6.
Ascher E, Hanson JN, Salles-Cunha S, Hingorani A. Lesser saphenous vein thrombophlebit is: its natural history and implicat ions for management . Vasc Endovascular Surg. 2003;37:421-7.
Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Ant ithrombot ic therapy for venous thromboembolic disease. Chest . 2001;119(1 Suppl):176S-93S.
Wichers IM, Haighton M, Büller HR, Middeldorp S. A ret rospective analysis of pat ients t reated for superfi cial vein thrombosis. Neth J Med. 2008;66:423-7.
Hill SL, Hancock DH, Webb TL. Thrombophlebit is of the great saphenous vein–recommendat ions for t reatment . Phlebology. 2008;23:35-9.
Cesarone MR, Belcaro G, Agus G, Georgiev M, Errichi BM, Marinucci R, et al. Management of superfi cial vein thrombosis and thrombophlebit is: status and expert opinion document . Angiology. 2007;58 Suppl 1:7S-14S.
Wichers IM, Di Nisio M, Buller HR, Middeldorp S. Treatment of superfi cial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systemat ic review. Haematologica. 2005;90:672-7.
Marchiori A, Mosena L, Prandoni P. Superfi cial vein thrombosis: risk factors, diagnosis, and t reatment . Semin Thromb Hemost . 2006;32:737-43.
Belcaro G, Nicolaides AN, Errichi BM, Cesarone MR, De Sanct is MT, Incandela L, et al. Superfi cial thrombophlebit is of the legs: a randomized, cont rolled, follow-up study. Angiology. 1999;50:523-9.
Lozano FS, Almazán A. Low-molecular-weight heparin versus saphenofemoral disconnect ion for the t reatment of above-knee greater saphenous thrombophlebit is: a prospect ive study. Vasc Endovascular Surg. 2003;37:415-20.
Titon JP, Auger D, Grange P, Hecquet JP, Remond A, Ulliac P, et al. Therapeut ic management of superfi cial venous thrombosis with calcium nadroparin. Dosage test ing and comparison with a non-steroidal ant i-infl ammatory agent . Ann Cardiol Angeiol (Paris). 1994;43:160-6.
Superf icial Thrombophlebit is Treated By Enoxaparin Study Group. A pi lot randomized double-bl ind comparison of a low-molecular-weight heparin, a nonsteroidal ant i-infl ammatory agent , and placebo in the t reatment of superf icial vein thrombosis. Arch Intern Med. 2003;163:1657-63.
Marchiori A, Verlato F, Sabbion P, Camporese G, Rosso F, Mosena L, et al. High versus low doses of unfract ionated heparin for the t reatment of superfi cial thrombophlebit is of the leg. A prospect ive, cont rolled, randomized study. Haematologica. 2002;87: 523-7.
Prandoni P, Tormene D, Pesavento R; Vesal io Invest igators Group. High vs. low doses of low-molecular-weight heparin for the t reatment of superfi cial vein thrombosis of the legs: a double-bl ind, randomized t rial . J Thromb Haemost . 2005;3: 1152-7.
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Ant ithrombot ic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Pract ice Guidelines (8th Edit ion). Chest . 2008;133(6 Suppl):454S-545S.
Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Ant ithrombot ic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Ant ithrombot ic and Thrombolyt ic Therapy. Chest . 2004;126(3 Suppl):401S-28S.
Di Nisio M, Wichers IM, Middeldorp S. Treatment for superfi cial thrombophlebit is of the leg. Cochrane Database Syst Rev. 2007;(2):CD004982.
Uncu H. A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an ant i-infl ammatory agent in the t reatment of superfi cial vein
thrombosis. Phlebology. 2009;24:56-60.
Decousus H, Prandoni P, Mismet t i P, Bauersachs RM, Boda Z, Brenner B, et al; CALISTO Study Group. Fondaparinux for the t reatment of superfi cial-vein thrombosis in the legs. N Engl J Med. 2010;363:1222-32.
Número de descargas:
23029
Número de visitas:
961
Citas:
0
